The FTC’s biologics workshop is underway!
By: Neal Hannan, Office of Policy Planning | Feb 3, 2014 4:29PM
A few minutes ago, FTC Chairwoman Edith Ramirez delivered opening remarks to kick off today’s FTC workshop exploring emerging issues affecting competition and patient access to biologic medicines.
You can view a live webcast of the workshop on the FTC’s website, or follow live tweets all day at #FTCFOB.
By: Neal Hannan, Office of Policy Planning | Feb 3, 2014 2:13PM
Tomorrow, the FTC will host a workshop to explore emerging issues affecting competition and consumer access to biologic medicines.
Competition to reduce the costs of biologic medicines
By: Elizabeth Jex, Office of Policy Planning | Dec 9, 2013 1:31PM
When faced with a major illness, patients usually want the best medicine available, regardless of cost. In some cases, next-generation “biologic” medicines may be the best treatments available. Unfortunately, these critical treatments can be very expensive. For example, Herceptin, used to treat breast cancer, can cost more than $50,000 a year; Remicade, which treats rheumatoid arthritis, more than $10,000 a year.
Continue Reading Competition to reduce the costs of biologic medicines
